Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced on Friday that Camostat mesilate (Camostat) has been added to the present ACTIV-2 Adaptive Platform Treatment Trial intended for outpatients with COVID-19 (Adapt Out COVID) that was introduced by the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG) in May 2020.
The trial will continue to assess monoclonal antibodies and other small molecules for outpatient COVID treatment. The product is the first orally administered agent to be included in the outpatient Adapt Out COVID trial.
Adapt Out COVID is a randomised, blinded, controlled adaptive platform trial that enables addition of investigational agents over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure. It also intends to determine if they are able to reduce viral shedding, thereby potentially preventing transmission of SARS-CoV-2 (the virus that causes COVID-19). The first oral dose of the product will be taken by the subjects at the enrolment visit and subsequent doses at home.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results